Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis

References

• Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147–334.
   PubMed Web of Science ®Google Scholar
• Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68:1102–1116.
   PubMed Web of Science ®Google Scholar
• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1–S84.
   PubMed Web of Science ®Google Scholar
• Ant K, Pearce N, Anderson HR, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) phase three. Allergy. 2009;64:123–148.
   PubMed Web of Science ®Google Scholar
• Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23–34.
   PubMedGoogle Scholar
• Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc. 2010;31:375–380.
   PubMed Web of Science ®Google Scholar
• Bielory L, Chun Y, Bielory BP, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy. 2011;66:686–693.
   PubMed Web of Science ®Google Scholar
• Samoliński B, Nowicka A, Wojas O, et al. Intranasal glucocorticosteroids – not only in allergic rhinitis in the 40th anniversary of intranasal glucocorticosteroids’ introduction. Otolaryngol Pol. 2014;68:51–64.
   PubMedGoogle Scholar
• Carr WW. New therapeutic options for allergic rhinitis: back to the future with intranasal corticosteroid aerosols. Am J Rhinol Allergy. 2013;27:309–313.
   PubMed Web of Science ®Google Scholar
• Fromer LM, Ortiz G, Ryan SF, et al. Insights on allergic rhinitis from the patient perspective. J Farm Pract. 2012;61:S16–S22.
   Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, et al. Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients. J Aerosol Med Pulm Drug Deliv. 2015;28:334–340.
   Web of Science ®Google Scholar
• Meltzer EO, Bensch GW, Storms WW. New intranasal formulations for the treatment of allergic rhinitis. Allergy Asthma Proc. 2014;35:S11–S19.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Rossi GA. The topical treatment of allergic and vasomotor rhinitis: the role of beclomethasone dipropionate. Recenti Prog Med. 2014;105:420–428.
   PubMedGoogle Scholar
• Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. Br Med J. 1973;4:464–466.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Willms DG, Guyatt GH, et al. Aqueous beclomethasone dipropionate nasal spray in the treatment of seasonal (ragweed) allergic rhinitis. Cmaj. 1992;147:887–892.
   PubMed Web of Science ®Google Scholar
• Ghimire A, Das BP, Mishra SC. Comparative efficacy of steroidal nasal spray versus antihistamine nasal spray in allergic rhinitis. Nep Med Coll J. 2007;9:1–10.
   PubMedGoogle Scholar
• Van As A, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol. 1993;91:1146–1154.
   PubMed Web of Science ®Google Scholar
• Scadding GK, Lund VJ, Jacques LA, et al. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy. 1995;25:737–743.
   PubMed Web of Science ®Google Scholar
• Haye R, Gomez EG. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology. 1993;31:169–174.
   PubMedGoogle Scholar
• Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy. 1996;51:569–576.
   PubMed Web of Science ®Google Scholar
• Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol. 1996;77:153–160.
   PubMed Web of Science ®Google Scholar
• Graft D, Aaronson D, Chervinsky P, et al. A placebo and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol. 1996;98:724–731.
   PubMed Web of Science ®Google Scholar
• Stelmach R, Nunes M, Ribeiro M, et al. Effect of treating allergic rhinitis with corticosteroids in patient with mild-to-moderate persistent asthma. Chest. 2005;128:3140–3147.
   PubMed Web of Science ®Google Scholar
• Profita M, Riccobono L, Bonanno A, et al. Effect of nebulized beclomethasone on airway inflammation and clinical status of children with allergic asthma and rhinitis: a randomized, double-blind, placebo controlled study. Int Arch Allergy Immunol. 2013;161:53–64.
   PubMed Web of Science ®Google Scholar
• Raphael GD, Berger WE, Prenner BM, et al. Efficacy, safety, and optimal dose selection of beclomethasone dipropionate nasal aerosol for seasonal allergic rhinitis in adolescents and adults. Curr Med Res Opin. 2013;29:1329–1340.
   PubMed Web of Science ®Google Scholar
• Van Bavel JH, Ratner PH, Amar NJ, et al. Efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2012;33:386–396.
   PubMed Web of Science ®Google Scholar
• Storms WW, Segall N, Mansfield LE, et al. Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2013;111:408–414.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Jacobs RL, LaForce CF, et al. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc. 2012;33:249–257.
   PubMed Web of Science ®Google Scholar
• Schenkel ER, Lumry WR, Kaiser HB, et al. Once-daily treatment with beclomethasone dipropionate nasal aerosol provides long term and sustained 24-hour nasal symptom relief in patients with periennal allergic rhinitis. J Allergy Clin Immunol. 2013;131(Suppl 2):AB113.
   Web of Science ®Google Scholar
• Wenstein SF, Andrews CP, Shah SR, et al. Long-term efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol. Allergy Asthma Proc. 2014;35:323–331.
   PubMed Web of Science ®Google Scholar
• Berger WE, Jacobs RL, Amar NJ, et al. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115:130–136.
   PubMed Web of Science ®Google Scholar
• Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Invest Allergy Clin Immunol. 2012;22:1–12.
   PubMed Web of Science ®Google Scholar
• Mener DJ, Shargorodsky J, Varadhan R, et al. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. Int Forum Allergy Rhinol. 2015;5:95–103.
   PubMed Web of Science ®Google Scholar
• Skoner D, Rachelefsky G, Meltzer E, et al. Detection of growth suppression in children during treatment with intranasal belcomethasone dipropionate. Pediatrics. 2000;105:e23.
   PubMed Web of Science ®Google Scholar
• Ratner PH, Miller SD, Hampel FC Jr, et al. Once -daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function. Ann Allergy Asthma Immunol. 2012;109:336–341.
   PubMed Web of Science ®Google Scholar
• Hampel FC Jr, Nayak NA, Segall N, et al. No hypothalamic-pituitary-adrenal function effect with beclomethasone dipropionate nasal aerosol, based on 24-hour serum cortisol in pediatric allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115:137–142.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br JClin Pharmacol. 2001;51:400–409.
   Web of Science ®Google Scholar
• Ratner PH, Melchior A, Dunbar SA, et al. Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. Clin Ther. 2012;34:1422e1431.
   Web of Science ®Google Scholar
• Bruni FM, De Luca G, Venturoli V, et al. Intranasal corticosteroids and adrenal suppression. Neuroimmunomodulation. 2009;16:353–362.
   PubMed Web of Science ®Google Scholar
• Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. Am J Otolaryngol. 2008;29:403–413.
   PubMed Web of Science ®Google Scholar
• Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2007;28:145–152.
   PubMed Web of Science ®Google Scholar
• Benninger MS, Hadley JA, Osguthorpe JD, et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg. 2004;130:5–24.
   PubMed Web of Science ®Google Scholar
• Teva Respiratory LLC. QNASL nasal aerosol [package insert]. Horsham (PA): Teva Respiratory, LLC; 2012. Last revised: March, 2014.
   Google Scholar
• Sunovian Pharmaceuticals, Inc. Zetonna (ciclesonide) nasal aerosol [prescribing information]. Marlborough (MA): Sunovian Pharmaceuticals; 2012. Last revision: January 2012. GlaxoSmithKline. Veramyst (fluticasone furoate) nasal spray package insert. Researc Triangle Park, NC.
   Google Scholar
• Opatowsky I, Feldman RM, Gross R, et al. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995;102:177–179.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT, Meyer MS. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. Am J Ophthalmol. 1990;109:489–490.
   PubMed Web of Science ®Google Scholar
• Teper A, Ratner PH. Mometasone furoate nasal spray is safe and effective for one-year treatment of children with perennial allergic rhinitis. J Allergy Clin Immunol. 2008;121(suppl 2):S52.
   Web of Science ®Google Scholar
• Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, et al. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg. 2004;130:187–191.
   PubMed Web of Science ®Google Scholar
• Ernst P, Baltzan M, Deschênes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Resp J. 2006;27:1168–1174.
   PubMed Web of Science ®Google Scholar
• Chylack LT Jr, Gross GN, Pedinoff A. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity. J Asthma. 2008;45:893–902.
   PubMed Web of Science ®Google Scholar